Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 6,630,017 shares, a growth of 106.5% from the June 30th total of 3,211,049 shares. Based on an average daily volume of 3,660,812 shares, the short-interest ratio is presently 1.8 days. Currently, 7.6% of the company’s stock are sold short.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Context Therapeutics in the fourth quarter worth about $43,000. Sanctuary Advisors LLC purchased a new position in shares of Context Therapeutics in the 1st quarter valued at approximately $51,000. Quadrature Capital Ltd acquired a new stake in Context Therapeutics in the 4th quarter worth approximately $68,000. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the 3rd quarter worth approximately $100,000. Finally, XTX Topco Ltd increased its stake in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CNTX shares. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Friday, July 17th. Finally, Maxim Group decreased their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Context Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $6.17.

Context Therapeutics Stock Down 1.9%

Shares of CNTX opened at $0.60 on Friday. The company has a 50 day moving average of $1.12 and a two-hundred day moving average of $1.95. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $3.62. The company has a market cap of $55.59 million, a price-to-earnings ratio of -1.44 and a beta of 1.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, sell-side analysts expect that Context Therapeutics will post -0.39 EPS for the current year.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.